Format

Send to

Choose Destination
Obstet Gynecol. 1998 Aug;92(2):292-8.

Cost-benefit analysis of first-void urine Chlamydia trachomatis screening program.

Author information

1
Department of Obstetrics and Gynecology and the Haartman Institute, University of Helsinki, Finland. jpaavone@cc.helsinki.fi

Abstract

OBJECTIVE:

To perform a cost-benefit analysis of a Chlamydia trachomatis screening program based on first-void urine testing of asymptomatic women using a polymerase chain reaction (PCR) test.

METHODS:

A decision tree was developed. Selected variables based on assumptions were subjected to sensitivity analyses to make the model accurate and defensible.

RESULTS:

Screening for chlamydial infections using the PCR test was shown to be cost-effective even in low-prevalence populations. Compared with a symptom-driven no-screening situation, a universal C trachomatis screening program using the PCR test would save money, in terms of direct cost, when the baseline prevalence of C trachomatis infection exceeds 3.9%.

CONCLUSION:

Cost analyses are still rare among trials that compare pharmacologic or procedural health care interventions. Socioeconomic studies linking secondary prevention of C trachomatis infection and infertility and adverse pregnancy outcome are needed to convince public health authorities of the need for and the benefit of such programs.

PMID:
9699769
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center